Lixisenatide (Lyxumia®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013001031
English
Authors' recommendations:
Lixisenatide (Lyxumia®) is recommended as an option for restricted use within NHS Wales. Lixisenatide (Lyxumia®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control: • In combination with basal insulin, with or without oral glucose-lowering medicinal products, in patients uncontrolled on basal insulin; • In combination with oral glucose-lowering medicinal products in patients uncontrolled on two or more oral glucose-lowering medicinal products. Lixisenatide (Lyxumia®) is not recommended for use within NHS Wales outside of these circumstances.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/863
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Diabetes Mellitus, Type 2
- Peptides
- Hypoglycemic Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.